Until the development of trastuzumab, a highly-specific monoclonal antibody targeted against human epidermal growth factor receptor 2 (HER2), breast cancer (BC) with positive HER2 was an aggressive and rapidly proliferating malignancy with a poor prognosis. Here, ERBB2 is linked to breast carcinoma.